Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2007-09-10 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a press release dated 2007-09-10 announcing the presentation of new preclinical data for a Hepatitis C protease inhibitor (TMC435350) at an upcoming symposium. It details the scientific findings (inhibition of HCV, combination effects) and mentions that the substance is currently undergoing Phase I studies, with initial clinical data expected at a future meeting (AASLD Liver Meeting in November). This content relates to ongoing research, development, and scientific updates, which is often shared with investors and the public. It is not a formal regulatory filing (like 10-K or IR), a financial results release (ER), or a management change announcement (MANG). Since it is a specific announcement about scientific progress and future data presentation, it fits best under the general category of Investor Relations material that doesn't fit a more specific financial or corporate action code. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release detailing scientific/pipeline progress that isn't explicitly covered by other codes like ER, CT, or IP, although 'IP' (Investor Presentation) is close, this is a press release, not a formal presentation document. However, RNS serves as the general regulatory/announcement fallback.
2007-09-10 Swedish
Board/Management Information 2007
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of a new Vice President of Sales & Marketing, Stefan Mårtensson, who will join the Medivir management team. This directly relates to changes in senior management personnel. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2007-09-06 English
Board/Management Information 2007
Board/Management Information Classification · 99% confidence The document is a press release dated 2007-09-06 announcing that Stefan Mårtensson has been hired as Vice President Sales & Marketing and will join the management group. This directly relates to a change in the company's senior management team. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category (MANG). The document is short and is an announcement, not a comprehensive report.
2007-09-06 Swedish
Interim / Quarterly Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Medivir AB covering the period from January 1 to June 30, 2007. It contains detailed financial statements (net sales, profit/loss, cash flow, earnings per share), management commentary on business trends, project portfolio updates, and operational highlights. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis itself. It fits the definition of an Interim/Quarterly Report (IR). H2 2007
2007-07-09 Swedish
Interim / Quarterly Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 1 January – 30 June 2007' and contains detailed financial statements, including consolidated net sales, loss after tax, liquid funds, and earnings per share. It also provides a comprehensive management discussion of business operations, clinical study progress, and project portfolios. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2007
2007-07-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.